2024-09-01 - Analysis Report
## JNJ Stock Analysis Report

**Company:** Johnson & Johnson (JNJ) - A multinational pharmaceutical, medical device, and consumer packaged goods company.

**Performance vs. S&P 500 (VOO):**
* JNJ has underperformed the S&P 500 by **-69.78%** over the period analyzed. This means its cumulative return is significantly lower than the index's. 
* The current relative divergence is **12.84%**, indicating that JNJ's performance is within the lower quartile compared to historical performance. 

**Recent Price Movement:**
* **Closing Price:** $165.86
* **5-Day Moving Average:** $164.31
* **20-Day Moving Average:** $161.22
* **60-Day Moving Average:** $154.17

**Technical Indicators:**
* **RSI (74.35):** JNJ is currently in overbought territory, suggesting a potential short-term correction could be imminent. 
* **PPO (0.09):** The PPO is positive but low, indicating a neutral to slightly bullish sentiment.
* **Delta_Previous_Relative_Divergence (-9.44):** JNJ's short-term relative divergence has been declining, indicating potential weakness in the near future.

**Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-25 | 1.95 | 22.45 B$ |
| 2024-05-01 | 1.35 | 21.38 B$ |
| 2024-02-16 | 1.68 | 21.39 B$ |
| 2023-10-27 | 10.32 | 21.35 B$ |
| 2024-02-16 | 10.32 | 21.35 B$ |

* The most recent earnings report (2024-07-25) shows an EPS of 1.95 and revenue of $22.45B. While the revenue beat expectations, the EPS slightly missed analyst estimates. 
* The company faces challenges in its pharmaceutical division with patent expirations on key drugs, which could impact future earnings. However, the medical device and consumer goods segments are showing stable growth.

**Overall Analysis:**

JNJ is currently trading at an overbought level with recent technical indicators suggesting potential weakness in the near term. While the company shows strong revenue growth, the pharmaceutical division faces challenges with patent expirations. This underperformance compared to the broader market (S&P 500) needs to be considered. 

Despite the current indicators, JNJ's long-term growth prospects remain positive with its strong presence in the healthcare sector and diversified product portfolio. Investors should carefully monitor the company's earnings reports and developments within the pharmaceutical division to determine the long-term investment strategy.